What side effects are associated with this type of intervention?

Common treatments for alcoholism include medications like naltrexone, acamprosate, and disulfiram, as well as brief interventions. Naltrexone can cause side effects such as nausea, headache, dizziness, and fatigue. Acamprosate may lead to diarrhea, anxiety, and insomnia. Disulfiram can cause drowsiness, headache, and a metallic or garlic-like taste, and it can lead to severe reactions if alcohol is consumed. Brief interventions, which focus on counseling and behavioral strategies, generally have no significant side effects but require patient engagement and adherence to be effective.

What prior FDA approvals exist?

The FDA has approved several medications for the treatment of alcohol use disorder. Naltrexone, an opioid receptor antagonist, helps reduce cravings and the rewarding effects of alcohol. Acamprosate, which modulates glutamate neurotransmission, is used to maintain abstinence in individuals who have stopped drinking. Disulfiram, an aldehyde dehydrogenase inhibitor, causes unpleasant effects when alcohol is consumed, thus deterring drinking. Gabapentin, although not FDA-approved specifically for alcohol use disorder, has shown efficacy in reducing alcohol consumption and withdrawal symptoms in clinical trials. These medications are part of a broader strategy to manage alcohol use disorder, often in combination with behavioral interventions.

What other types of research exist?

Promising novel alternatives to Brief Intervention for alcoholism patients include: 1) Technology-enhanced interventions such as web-based CBT programs and smartphone applications, which have shown efficacy in increasing abstinence rates. 2) Multimodal approaches that combine motivational interviewing, contingency management, and cognitive-behavioral therapy (CBT) to address multiple clinical needs. 3) Family-involved therapies like Behavioral Family Counseling, which leverage family support to reinforce abstinence and improve treatment outcomes.

← Back to Search

Behavioral Intervention

Motivational Interviewing for HIV/AIDS and Alcohol Use

N/A

Waitlist Available

Led By Amy C Justice, MD, PhD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 30 days post intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial is designed for HIV patients who are on multiple medications and consume alcohol. It aims to help them manage symptoms caused by the interaction between alcohol and their medications.

Who is the study for?

This trial is for HIV patients who are part of the VACS and MASH studies, take 5 or more medications, and have consumed alcohol in the last month. They must not have been diagnosed with a severe alcohol use disorder in the past year.

What is being tested?

The HARP study tests a brief intervention combining Information-Motivation-Behavioral Skills (IMB) with motivational interviewing techniques to address symptoms affected by alcohol and medication interactions in HIV patients.

What are the potential side effects?

While specific side effects aren't listed for this behavioral intervention, participants may experience discomfort discussing personal habits like medication use and alcohol consumption.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 30 days post intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 30 days post intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 30 days post intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HIV Vaccine

Body Weight Changes

Number of Medications Prescribed Post Intervention

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: HIV Medications and Alcohol UseExperimental Treatment1 Intervention

Participants with HIV who take 5 or more medications and currently (within the past month) consume alcohol

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

IMB-motivational interviewing (MI) techniques (IMB-MI)

2023

N/A

~50

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for alcoholism include pharmacologic agents like naltrexone, acamprosate, and disulfiram, as well as psychosocial interventions such as cognitive-behavioral therapy (CBT) and brief interventions. Naltrexone works by blocking opioid receptors, reducing the rewarding effects of alcohol, while acamprosate modulates glutamate neurotransmission to stabilize brain activity. Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, causing unpleasant reactions when alcohol is consumed. Psychosocial interventions like CBT help patients identify and cope with high-risk situations, and brief interventions focus on immediate behavioral changes. These treatments are crucial as they address both the biological and behavioral aspects of alcoholism, improving overall treatment outcomes and reducing adverse symptoms from alcohol-medication interactions.

Variance in the Efficacy of Brief Interventions to Reduce Hazardous and Harmful Alcohol Consumption Between Injury and Noninjury Patients in Emergency Departments: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Therapy preference and treatment outcome in clients with mild to moderate alcohol dependence.Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study.